Mother-to-child HIV Transmission
Conditions
Keywords
HIV, PMTCT, Antenatal Care
Brief summary
The study design includes an observational prospective cohort of HIV-positive pregnant/postpartum women and their infants enrolled during antenatal clinics (or immediately postpartum) from prevention of mother-to-child transmission (PMTCT) programs and followed until the infants reach the age of 18 - 24 months and semi-structure interviews with a sub-set of these women. A second study component involves semi-structured interviews with health care workers (HCW) involved in the PMTCT programs and yearly facility surveys at the selected study facilities.
Interventions
OTHERStandard of care
OTHERSemi-structured interviews
Sponsors
Elizabeth Glaser Pediatric AIDS Foundation
Ministry of Health, Rwanda
University of Rwanda
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Documented HIV infection * Pregnant, in the last trimester of pregnancy or within two weeks post-delivery. * Participation in the PMTCT program during antenatal care at one of the study sites * Planning on remaining in the Kigali area after delivery * Able and willing to give informed consent for study participation for herself and her infant(s). If a pregnant woman is less than 18 years of age and still living with her parents, informed consent will also be required from one of her parents
Exclusion criteria
* Women not willing to provide informed consent to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 18 - 24 month HIV-free survival of children born to HIV-positive pregnant women | 18 - 24 months |
Secondary
| Measure | Time frame |
|---|---|
| HIV-exposed infants with stunting, underweight, or wasting Infants and young children breastfed (exclusive or any breastfeeding) at various ages | 18 - 24 months |
| Infants and young children breastfed (exclusive or any breastfeeding) at various ages | 18 - 24 months |
| Adherence to the universal antiretroviral therapy (ARV) regimen among pregnant and postpartum women (Option B+) and their HIV-exposed children, including the proportion of study women with HIV RNA < 1000 copies/ml or > 2 log10 copies/mL decrease in viral | 18 - 24 months |
Countries
Rwanda
Contacts
PRINCIPAL_INVESTIGATOREmily A. Bobrow, PhD, MPH
Elizabeth Glaser Pediatric AIDS Foundation
Outcome results
None listed